Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection for chronic weight management, the company said in an announcement on Friday.
The country’s largest drug maker will launch generic semaglutide injection under the brand name Noveltreat after the expiry of its patent in India.
Danish drug maker Novo Nordisk’s patent for the blockbuster weight-loss and diabetes molecule semaglutide (sold under brand names Ozempic and Wegovy) expires end-March, which is driving top Indian pharma companies such as Sun, Dr Reddy’s and a raft of others to line up generics launches over the upcoming months.
“Obesity and diabetes have emerged as two of the most pressing health challenges confronting India and GLP-1 based therapies can play a meaningful role in addressing this growing burden,” said Kirti Ganorkar, Managing Director, Sun Pharma. “Noveltreat meets global quality standards and is supported by robust Indian clinical evidence on efficacy and safety for weight management,” he added.
Sun said its product has received approval from the DCGI following a review of a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths - 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, with a maintenance dose of 2.4 mg once weekly. The product is administered via a prefilled pen.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity.
In December 2025, Sun Pharma received DCGI approval for manufacturing and marketing semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It will be launched under the brand name Sematrinity, after the expiry of semaglutide patent in India.
The country’s largest drug maker will launch generic semaglutide injection under the brand name Noveltreat after the expiry of its patent in India.
Danish drug maker Novo Nordisk’s patent for the blockbuster weight-loss and diabetes molecule semaglutide (sold under brand names Ozempic and Wegovy) expires end-March, which is driving top Indian pharma companies such as Sun, Dr Reddy’s and a raft of others to line up generics launches over the upcoming months.
“Obesity and diabetes have emerged as two of the most pressing health challenges confronting India and GLP-1 based therapies can play a meaningful role in addressing this growing burden,” said Kirti Ganorkar, Managing Director, Sun Pharma. “Noveltreat meets global quality standards and is supported by robust Indian clinical evidence on efficacy and safety for weight management,” he added.
Sun said its product has received approval from the DCGI following a review of a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths - 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, with a maintenance dose of 2.4 mg once weekly. The product is administered via a prefilled pen.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity.
In December 2025, Sun Pharma received DCGI approval for manufacturing and marketing semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It will be launched under the brand name Sematrinity, after the expiry of semaglutide patent in India.
